中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于合肥立方制药股份有限公司 2025年第二次临时股东会的法律意见书 致：合肥立方制药股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受合肥立方制药股份有限 公司（以下简称"公司"）的委托，指派本所律师列席公司于 2025 年 11 月 17 日 下午 15 时在安徽省合肥市文曲路 446 号科研综合楼五楼会议中心召开的 2025 年第二次临时股东会（以下称"本次股东会"），并依据《中华人民共和国公司法》 等中国法律、法规和相关规范性文件（以下称"中国法律法规"）及《合肥立方制 药股份有限公司章程》（以下称"公司章程"）的规定，就本次股东会的召集和召 开程序、出席会议人员资格、召集人资格、会议表决程序和表决结果等事宜（以 下称"程序事宜"）出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东会的文件， 包括但不限于公司第六届董事会第二次会议决议以及根据上述决议内容刊登的 公告、本次股东会的通知、议案 ...

Core Viewpoint - Aipeng Medical and Cube Pharmaceutical signed a strategic cooperation framework agreement to establish a joint innovation center focusing on rapid response mechanisms for clinical needs, technology research and development, and achievement transformation [1] Group 1: Strategic Cooperation - The partnership aims to conduct joint research on AI, brain-computer interfaces, and drug efficacy evaluation [1] - The collaboration will promote coordinated clinical research between medical devices and pharmaceuticals [1] Group 2: Academic and Social Engagement - Both companies will collaborate with academic institutions and industry associations to facilitate scientific exchanges and public awareness activities [1] - The initiative aims to enhance standardized diagnosis and treatment of ADHD and improve social recognition [1]

Group 1 - The core viewpoint of the news is that Lifan Pharmaceutical's stock has increased by 5.37%, reaching a price of 28.46 CNY per share, with a total market capitalization of 5.413 billion CNY as of the report date [1] - Lifan Pharmaceutical, established on July 16, 2002, and listed on December 15, 2020, is primarily engaged in the research, production, and sales of pharmaceutical formulations and raw materials, with 97.50% of its revenue coming from pharmaceutical products [1] - The company has a trading volume of 91.038 million CNY and a turnover rate of 2.38% [1] Group 2 - In the context of major shareholders, Invesco Great Wall Fund's healthcare mixed fund has entered the top ten circulating shareholders of Lifan Pharmaceutical, holding 910,100 shares, which is 0.66% of the circulating shares [2] - The Invesco Great Wall Healthcare Mixed A Fund (011876) has achieved a year-to-date return of 28.64% and a one-year return of 24.58%, ranking 3331 out of 8154 and 3709 out of 8046 in its category, respectively [2] - The fund was established on August 18, 2021, and has a current scale of 368 million CNY, with an estimated floating profit of approximately 1.3196 million CNY from its investment in Lifan Pharmaceutical [2]

Core Insights - Cube Pharmaceuticals (003020.SZ) reported its Q3 2025 results on October 30, 2025, highlighting a total of 39.4014 million A-shares held by three institutional investors, representing 20.72% of the company's total share capital [1] Institutional Holdings - The institutional investors include Hefei Cube Investment Group Co., Ltd., China Merchants Fund Management Co., Ltd. - Social Security Fund 2108 Portfolio, and China Minsheng Bank Co., Ltd. - Invesco Great Wall Medical Health Mixed Securities Investment Fund [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 0.06 percentage points [1] Public Fund Activity - One new public fund disclosed its holdings in Cube Pharmaceuticals this quarter, specifically Invesco Great Wall Medical Health Mixed Class A [1] - A total of 60 public funds were not disclosed in this quarter compared to the previous one, including Hai Fu Tong Growth Value Mixed A, CITIC Construction Investment Rotation Mixed A, and others [1] Social Security Fund - One new social security fund disclosed its holdings in Cube Pharmaceuticals, which is the China Merchants Fund Management Co., Ltd. - Social Security Fund 2108 Portfolio [1]

Core Viewpoint - Lifan Pharmaceutical (003020.SZ) reported a decline in revenue for the first three quarters of 2025, while net profit showed a slight increase, indicating mixed financial performance [1] Financial Performance - The company achieved an operating revenue of 1.081 billion yuan, a year-on-year decrease of 3.95% [1] - The net profit attributable to shareholders of the listed company was 121 million yuan, reflecting a year-on-year increase of 1.65% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 89.35 million yuan, which represents a year-on-year decrease of 20.23% [1] - Basic earnings per share stood at 0.64 yuan [1]

Core Viewpoint - The company reported a decline in revenue for the first three quarters of 2025, while net profit showed a slight increase, indicating mixed financial performance [1] Financial Performance - The company achieved operating revenue of 1.081 billion yuan for the first three quarters, representing a year-on-year decrease of 3.95% [1] - The net profit attributable to shareholders of the listed company was 121 million yuan, reflecting a year-on-year increase of 1.65% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 89.35 million yuan, which is a year-on-year decrease of 20.23% [1]

Company Overview - Lifan Pharmaceutical (SZ 003020) announced the convening of its sixth second board meeting on October 28, 2025, to review the proposal for the "2025 Third Quarter Report" [1] - As of the report, Lifan Pharmaceutical has a market capitalization of 5.4 billion yuan [1] Revenue Composition - For the first half of 2025, Lifan Pharmaceutical's revenue composition is as follows: - Pharmaceutical manufacturing accounted for 91.14% - Pharmaceutical retail accounted for 7.71% - Other segments accounted for 1.16% [1]

证券代码：003020 证券简称：立方制药 公告编号：2025-073 合肥立方制药股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规 则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、 行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 17 日 15:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 17 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具 体时间为 2025 年 11 月 17 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 7、出席对象： （1）在股权登记日持有公 ...

证券代码：003020 证券简称：立方制药 公告编号：2025-070 合肥立方制药股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 合肥立方制药股份有限公司（以下简称"公司"）第六届董事会第二次会议 于 2025 年 10 月 24 日以电子邮件、电话、短信等方式通知公司全体董事。会议 于 2025 年 10 月 28 日在公司会议室以现场结合通讯表决方式召开，会议应出席 董事 8 人，实际出席董事 8 人，其中以通讯方式出席会议董事 3 人，董事崔欢喜 先生及独立董事杨模荣先生、李进华先生以通讯方式出席会议并表决。公司高级 管理人员列席了会议。会议由公司董事长季俊虬先生主持。 本次董事会会议的召集、召开程序符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定。 二、董事会会议审议情况 与会董事经过认真审议并投票表决，审议通过了如下议案： 本议案已经第六届董事会审计委员会第二次会议审议通过。 具体内容详见公司同日在《证券时报》《上海证券报》和巨潮资讯网 （http://www. ...

证券代码：003020 证券简称：立方制药 公告编号：2025-072 合肥立方制药股份有限公司 （二）本次利润分配预案的合法性、合规性 本次2025年中期利润分配预案符合《中华人民共和国公司法》《上市公司 关于 2025 年中期利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 合肥立方制药股份有限公司（以下称"公司"）于2025年10月28日召开第 六届董事会第二次会议，审议通过了《关于2025年中期利润分配预案的议案》， 根据《公司章程》的规定，本议案尚需提交公司股东会审议通过。现将具体情 况公告如下： 一、2025年中期利润分配预案基本情况 （一）利润分配预案的具体内容 根据公司 2025 年第三季度财务报告（未经审计），2025 年前三季度，公 司实现合并归属于上市公司股东的净利润 120,941,686.73 元，合并报表期末可 供分配的利润为 1,005,683,946.87 元，母公司报表期末可供分配的利润为 961,390,806.95 元，根据合并报表和母公司报表中可供分配利润孰低的原则，公 司可供股东分配的利润为 961, ...